Evidence map›Paper›PMID 38507510›Full record

ArticleHypertension (Dallas, Tex. : 1979)2024

Kidney Renin-Angiotensin System: Lost in a RAS Cascade.

Steven D Crowley, L Gabriel Navar, Minolfa C Prieto, Susan B Gurley, Thomas M Coffman

Open access · greenAbstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. A key role of ATAmerican journal of physiology. Renal physiology · 2025
    Article
  4. Article
  5. Angiotensin Dysregulation in Patients with Arterial Aneurysms.International journal of molecular sciences · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Deletion of ATAmerican journal of physiology. Renal physiology · 2024
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Steven D CrowleyDivision of Nephrology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, NC (S.D.C.).ORCID 0000-0002-1838-0561
L Gabriel NavarDepartment of Physiology and Renal and Hypertension Center, Tulane University School of Medicine, New Orleans, LA (L.G.N., M.C.P.).ORCID 0000-0002-3777-7564
Minolfa C PrietoDepartment of Physiology and Renal and Hypertension Center, Tulane University School of Medicine, New Orleans, LA (L.G.N., M.C.P.).
Susan B GurleyDivision of Nephrology and Hypertension, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (S.B.G.).
Thomas M CoffmanCardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore (T.M.C.).ORCID 0000-0002-8433-1629
Tulane University · USDurham VA Medical Center · USNational University of Singapore · SGUniversity of Southern California · US

Funding

The role of the M1 macrophage response in the progression of chronic kidney diseaseI01BX000893 · VA · DURHAM VA MEDICAL CENTER · PI Steven D Crowley · 2012 to 2026
–
BLRD VA I01 BX000893
6 · The paper itself

Abstract

Renin was discovered more than a century ago. Since then, the functions of the renin-angiotensin system in the kidney have been the focus of intensive research revealing its importance in regulation of renal physiology and in the pathogenesis of heart, vascular, and kidney diseases. Inhibitors of renin-angiotensin system components are now foundational therapies for a range of kidney and cardiovascular diseases from hypertension to heart failure to diabetic nephropathy. Despite years of voluminous research, emerging studies continue to reveal new complexities of the regulation of the renin-angiotensin system within the kidney and identification of nonclassical components of the system like the prorenin receptor (PRR) and ACE2 (angiotensin-converting enzyme 2), with powerful renal effects that ultimately impact the broader cardiovascular system. With the emergence of a range of novel therapies for cardiovascular and kidney diseases, the importance of a detailed understanding of the renin-angiotensin system in the kidney will allow for the development of informed complementary approaches for combinations of treatments that will optimally promote health and longevity over the century ahead.

Indexed as

Diabetic NephropathiesHypertensionHealth PromotionHumansKidneyReninRenin-Angiotensin SystemRenincardiovascular diseasesheart failurehypertensionkidneyrenin–angiotensin system

Identifiers

PMID38507510
PMCPMC10957093
OpenAlexW4392982778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.